The company manages its investments on a decentralized basis and its involvement is concentrated on the provision of support rather than on being involved in the day-to-day management of business units of investees. Key investments include Mediclinic (50%), OUTsurance Group (30.6%), CIVH (57%), RCL Foods (79.9%), and stakes in FirstRand and Discovery, which contribute approximately 88% to Remgro's intrinsic net asset value. The company's portfolio positioning provides exposure to multiple growth sectors with significant board influence while maintaining operational autonomy of subsidiaries.
In 2025, Remgro's revenue was 51.51 billion ZAR (up 2.15%) with earnings of 3.30 billion ZAR (up 166.16%). However, the company faces valuation challenges and strategic headwinds. Remgro's CIVH-Vodacom merger is blocked, and its investment in South Africa's telecommunications sector through CIVH is hitting challenges. The strong recovery in 2025 earnings is offset by a discount to intrinsic value.
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.
Open report →